{
  "content_blocks": [
    {
      "type": "heading_2",
      "content": {
        "text": "報告案：111年新功能類別特材預算與107-110年收載特材使用情形"
      }
    },
    {
      "type": "callout",
      "content": {
        "icon": "📋",
        "style": "info",
        "text": "本報告旨在說明111年（2022年）新功能類別特材預算之支用情形，以及107年至110年（2018-2021年）健保收載新特材的申報狀況與預算支用結果。報告共200頁。"
      }
    },
    {
      "type": "heading_2",
      "content": {
        "text": "說明一：111年新功能類別特材預算之用情形"
      }
    },
    {
      "type": "bullet_list",
      "content": {
        "items": [
          "醫院總額部門：111年新功能特材預算為76.4億元。",
          "截至111年10月，已完成公告實施135項新特材及修訂給付規定，推估預算約79.4億元。",
          "截至111年10月，有效品項計134項及修訂給付規定，推估預算約79.4億元。"
        ]
      }
    },
    {
      "type": "toggle_list",
      "content": {
        "title": "重點特材支用情形",
        "items": [
          {
            "title": "經導管置換瓣膜套組 (TAVI)",
            "content": [
              {
                "type": "bullet_list",
                "content": {
                  "items": [
                    "原屬自費特材，經111年9月委員會討論通過，自111年11月1日起改列健保全額給付，其不足預算將由112年新醫療科技預算支應。",
                    "自110年2月1日至111年8月，累計申報量為935組，申報點數為10.21億點。",
                    "推估累計至111年12月申報點數為12.85億點，與原預算編列13.65億點相比，未超出預算數。",
                    "111年1-2月申報量為109組，推估111年全年達660組，高於原預估使用量357組。",
                    "為合理使用並降低健保財務衝擊，於111年3月函詢學會修訂給付規定。",
                    "經111年5月委員會討論通過，給付規定由事前審查改為特殊專案審查，並刪除年齡限制，臨床治療回歸風險評估，自111年7月1日公告生效。",
                    "8月申報量為31組，較去年同期43組減少12組。將持續監控並啟動加量協議。"
                  ]
                }
              }
            ]
          },
          {
            "title": "總體新增品項及西醫基層",
            "content": [
              {
                "type": "bullet_list",
                "content": {
                  "items": [
                    "總體新增品項：經扣減被替代品項點數後，111年1-8月實際申報點數約1.41億點，推估全年約2.11億點，未超出預算數。",
                    "西醫基層：111年未編列預算，亦無申報量。"
                  ]
                }
              }
            ]
          }
        ]
      }
    },
    {
      "type": "heading_2",
      "content": {
        "text": "說明二：107-110年新收載特材申報情形及預算支用結果"
      }
    },
    {
      "type": "toggle_list",
      "content": {
        "title": "年度報告",
        "items": [
          {
            "title": "107年新收載特材申報情形",
            "content": [
              {
                "type": "bullet_list",
                "content": {
                  "items": [
                    "醫院總額部門新功能特材預算為4.55億元，預算導入至111年約5.41億元。",
                    "107年共計導入實施24類特材、72品項，推估預算約4.53億元。",
                    "截至111年10月有效品項約100品項。",
                    "經扣減被替代品項點數後，111年1-8月實際申報點數為3.32億點，推估全年約4.98億點，未超出預算數。",
                    "西醫基層107年未編列預算，亦無申報量。"
                  ]
                }
              }
            ]
          },
          {
            "title": "108年新收載特材申報情形",
            "content": [
              {
                "type": "bullet_list",
                "content": {
                  "items": [
                    "醫院總額部門新功能特材預算為3.09億元，預算導入至111年約3.53億元。",
                    "108年共計導入實施15類特材、78品項。",
                    "截至111年10月有效品項計97品項。",
                    "經扣減被替代品項點數後，111年1-8月實際申報點數約1.22億點，推估全年約1.83億點，未超出預算數。",
                    "西醫基層108年未編列預算，亦無申報量。"
                  ]
                }
              }
            ]
          },
          {
            "title": "109年新收載特材申報情形",
            "content": [
              {
                "type": "bullet_list",
                "content": {
                  "items": [
                    "醫院總額部門新功能特材預算為6.91億元，預算導入至111年約7.48億元。",
                    "109年本會議通過實施19類特材、18品項，實際於109年公告實施14類特材、44品項，推估約1.58億元。",
                    "5類特材24品項陸續於111年1月1日及2月1日公告生效，財務推估約5.21億元，其預算已納入該期。",
                    "截至111年10月有效品項計85品項。",
                    "經扣減被替代品項點數後，111年1-8月實際申報點數約7.03億點，推估全年約10.54億點。",
                    "超出預算數約3.65億點，主要包含高價及臨床需求醫材，申報點數高於原預估費用。"
                  ]
                }
              },
              {
                "type": "toggle_list",
                "content": {
                  "title": "超出預算之主要特材說明",
                  "items": [
                    {
                      "title": "刺激迷走神經治療系統 (VNS) 及髕骨脛骨關節系統",
                      "content": [
                        {
                          "type": "bullet_list",
                          "content": {
                            "items": [
                              "已採行加量協議內容調整支付點數。"
                            ]
                          }
                        }
                      ]
                    },
                    {
                      "title": "延祐萊鏡白內障",
                      "content": [
                        {
                          "type": "bullet_list",
                          "content": {
                            "items": [
                              "經111年5月委員會討論通過，針對後囊型白內障表徵及事前審查繳附照片，修訂給付規定，於111年7月1日生效。",
                              "8月申報量為58組，較去年同期73組減少15組。將持續密切監控觀察。"
                            ]
                          }
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "type": "bullet_list",
                "content": {
                  "items": [
                    "西醫基層：新醫療科技預算為1億元，共計導入實施2類特材、2品項，預估預算為116萬元。",
                    "截至111年10月有效品項為5品項。111年1-8月實際申報點數為65.7萬點，推估全年約98.5萬點，足以支應。"
                  ]
                }
              }
            ]
          },
          {
            "title": "110年新收載特材申報情形",
            "content": [
              {
                "type": "bullet_list",
                "content": {
                  "items": [
                    "醫院總額部門新功能特材預算為5.87億元，預算導入至111年約6.05億元。",
                    "110年共計導入實施21類特材、121品項。",
                    "截至111年10月有效品項為126品項。",
                    "經扣減被替代品項點數後，111年1-8月實際申報點數為2.01億點，推估全年約3.02億點，未超出預算數。",
                    "西醫基層：111年新功能特材預算為30萬元，係配合醫院總額部門新增特材，其使用涉及西醫基層範圍予以編列支應使用，無申報資料。"
                  ]
                }
              }
            ]
          }
        ]
      }
    },
    {
      "type": "heading_2",
      "content": {
        "text": "說明三：總結"
      }
    },
    {
      "type": "bullet_list",
      "content": {
        "items": [
          "從107年至110年（計5年）導入預算約30.12億元。",
          "從107年至111年10月新收載特材，經扣減被替代品項點數後，111年截至8月實際申報點數約15.03億點，推估111年全年約22.55億點。",
          "總體而言，未超出五年編列預算數。"
        ]
      }
    },
    {
      "type": "callout",
      "content": {
        "icon": "📋",
        "style": "info",
        "text": "本案擬持續監控費用申報情形。"
      }
    },
    {
      "type": "heading_2",
      "content": {
        "text": "說明四：後續監控機制"
      }
    },
    {
      "type": "bullet_list",
      "content": {
        "items": [
          "為持續監控新特材納入健保給付後之特材申報情形及預算支用結果，定期於本會議報告特材收載五年之申報情形。",
          "考量特材納入健保給付後，第一年申報量高於原預估量，第二年即採行加量協議調整支付點數或修訂給付規定等方式管理，第三年使用量趨於平穩，後續兩年較無變動。"
        ]
      }
    },
    {
      "type": "callout",
      "content": {
        "icon": "💡",
        "style": "info",
        "text": "建議參考本保險藥物給付項目及支付標準第61之1條及第50條之年限，往後與下次會議起，報告新功能特材收載三年之申報情形及預算支用結果。"
      }
    },
    {
      "type": "heading_2",
      "content": {
        "text": "補充說明：椎補水泥"
      }
    },
    {
      "type": "bullet_list",
      "content": {
        "items": [
          "共計32項，於111年3月本會議討論通過納入健保給付。",
          "自111年7月1日公告生效。",
          "截至111年8月，計26品項，申報點數約321.3萬點。",
          "推估全年申報點數約192萬點，未超出預算數。"
        ]
      }
    },
    {
      "type": "heading_2",
      "content": {
        "text": "委員發言與健保署回應"
      }
    },
    {
      "type": "toggle_list",
      "content": {
        "title": "委員一發言 (8:16-1:05:5)",
        "items": [
          {
            "title": "對於超出預算品項的追蹤成效",
            "content": [
              {
                "type": "bullet_list",
                "content": {
                  "items": [
                    "部分品項超出當初的預算，健保署已採取加量協議、特殊專案審查等措施。",
                    "建議應追蹤這些措施後的實際結果，例如調整後的預算與實際支用狀況，以及適應症增加或特殊審查後的實際情況如何。",
                    "報告只提及將採取措施，但未呈現措施後的結果，若加量協議仍未達預期，應如何處理？",
                    "即便總體五年預算未超支，個別超出當初預算預估的品項仍應提出檢討。"
                  ]
                }
              }
            ]
          },
          {
            "title": "對監控週期調整的看法",
            "content": [
              {
                "type": "bullet_list",
                "content": {
                  "items": [
                    "堅決反對將五年的監控週期縮短為三年，既然當初設定五年，就應維持五年，避免未來又改為兩年。",
                    "監控工作雖辛苦，但應持續進行，否則資料不易閱讀。"
                  ]
                }
              }
            ]
          },
          {
            "title": "健保署回應 (1:06:3-1:41:6)",
            "content": [
              {
                "type": "bullet_list",
                "content": {
                  "items": [
                    "感謝委員指導，健保署對「大水庫」（整體預算）與「小水庫」（個別品項）均有監控。",
                    "若品項使用量超過預測值1.2至1.3倍，即會啟動個別討論，例如股科、TAVI、刺激迷走神經治療系統等。",
                    "提案縮短為三年監控，是因經驗顯示第三年後使用量趨於平穩。",
                    "即便縮短報告週期，內部仍會持續進行監控並定期提出報告。"
                  ]
                }
              }
            ]
          }
        ]
      }
    },
    {
      "type": "toggle_list",
      "content": {
        "title": "委員二發言 (1:42:0-1:55:0)",
        "items": [
          {
            "title": "特定品項使用量超出預估問題",
            "content": [
              {
                "type": "bullet_list",
                "content": {
                  "items": [
                    "**肋骨固定植入板 (204頁)：** 當初年預估使用量為1530支，自5月1日生效，截至目前（4個月）已達1087支。若以此推算一年將達3261支，遠高於預估量，需特別注意。",
                    "**骨內注射針 (220頁)：** 主要用於急診病人。110年申報量為637支，但當初通過的預估量僅200支。目前（5個月）使用量已達868支。若以此推算一年約1300支，是原預估量的6倍，建議啟動加量協議。"
                  ]
                }
              }
            ]
          },
          {
            "title": "健保署回應 (1:55:0-2:03:0)",
            "content": [
              {
                "type": "bullet_list",
                "content": {
                  "items": [
                    "**肋骨固定植入板：** 承認使用量有所成長，部分病人可能在5月1日生效前等待。目前仍在監控中，預計明年初將在會議上報告。",
                    "**骨內注射針：** 將召集廠商進行加量協議，處理完畢後會再向本會議報告。"
                  ]
                }
              }
            ]
          }
        ]
      }
    },
    {
      "type": "toggle_list",
      "content": {
        "title": "委員一追問 (2:03:0-2:06:0)",
        "items": [
          {
            "title": "對「病人等待」解釋的質疑",
            "content": [
              {
                "type": "bullet_list",
                "content": {
                  "items": [
                    "對於肋骨固定植入板「病人等待」的解釋提出質疑，因為這是外傷急診治療，病人不應等待，這類情況怎麼可能延後治療？",
                    "這可能是當初專科醫學會低估或預估不準確，或給付規定存在模糊空間，建議檢視。"
                  ]
                }
              }
            ]
          },
          {
            "title": "健保署再回應 (2:06:0-2:09:0)",
            "content": [
              {
                "type": "bullet_list",
                "content": {
                  "items": [
                    "承認對「病人等待」的說法有「口誤」，急症病人確實不應等待。",
                    "肋骨固定植入板已啟動內部監控，將與相關專科醫學會共同討論給付規定是否明確，並於後續報告。"
                  ]
                }
              }
            ]
          }
        ]
      }
    }
  ],
  "action_items": [
    {
      "task": "持續追蹤超出預算特材之處置成效與結果：針對已超出預算之特材品項 (如經導管置換瓣膜套組、刺激迷走神經治療系統、髕骨脛骨關節系統、延祐萊鏡白內障等)，持續追蹤其採行之加量協議、修訂給付規定或特殊專案審查等措施後的實際預算支用狀況與成效，並於下次會議報告。",
      "owner": "健保署",
      "due_date": "N/A"
    },
    {
      "task": "提供超出預算特材之彙整報告：針對超出當初預估預算之特材品項，提供一份重點彙整報告，說明採取的行動及其結果。",
      "owner": "健保署",
      "due_date": "N/A"
    },
    {
      "task": "維持五年監控週期：維持現行新功能特材收載後五年之監控週期，而非縮短為三年。",
      "owner": "健保署",
      "due_date": "Ongoing"
    },
    {
      "task": "肋骨固定植入板使用量監控與給付規定檢討：針對肋骨固定植入板使用量超出預估之情形，持續監控其費用申報狀況，並與相關專科醫學會共同檢視給付規定是否存在模糊空間，必要時進行修訂，並於明年初會議上報告。",
      "owner": "健保署",
      "due_date": "N/A"
    },
    {
      "task": "骨內注射針議價：針對骨內注射針使用量超出預估之情形，與廠商進行加量協議（議價），並於後續會議報告處理結果。",
      "owner": "健保署",
      "due_date": "N/A"
    }
  ],
  "mindmap_structure": {
    "nodes": [
      {
        "id": "root",
        "data": {
          "label": "新功能特材預算與使用報告",
          "level": 0
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "strategy",
        "data": {
          "label": "戰略目標",
          "level": 1,
          "direction": "right",
          "color": "#2563eb",
          "icon": "🎯"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "strategy-budget-mgmt",
        "data": {
          "label": "特材預算管理",
          "level": 2,
          "color": "#2563eb"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "strategy-cost-compliance",
        "data": {
          "label": "確保費用合規",
          "level": 2,
          "color": "#2563eb"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "strategy-nhi-benefits",
        "data": {
          "label": "達成健保效益",
          "level": 2,
          "color": "#2563eb"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "ops",
        "data": {
          "label": "營運成果",
          "level": 1,
          "direction": "left",
          "color": "#16a34a",
          "icon": "📊"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "ops-2022-budget",
        "data": {
          "label": "111年預算支用",
          "level": 2,
          "color": "#16a34a"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "ops-2022-total-budget",
        "data": {
          "label": "總額預算: 76.4億",
          "level": 3,
          "color": "#16a34a"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "ops-2022-announced-items",
        "data": {
          "label": "已公告品項: 135項",
          "level": 3,
          "color": "#16a34a"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "ops-2022-estimated-spend",
        "data": {
          "label": "推估支用: 79.4億",
          "level": 3,
          "color": "#16a34a"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "ops-2018-2022-claim",
        "data": {
          "label": "107-111年總體申報",
          "level": 2,
          "color": "#16a34a"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "ops-5yr-budget",
        "data": {
          "label": "五年導入預算: 30.12億",
          "level": 3,
          "color": "#16a34a"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "ops-2022-estimated-claim",
        "data": {
          "label": "111年推估申報: 22.55億",
          "level": 3,
          "color": "#16a34a"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "ops-overall-within-budget",
        "data": {
          "label": "結果: 未超預算",
          "level": 3,
          "color": "#16a34a"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "ops-vertebroplasty-case",
        "data": {
          "label": "椎補水泥案例",
          "level": 2,
          "color": "#16a34a"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "ops-vp-items",
        "data": {
          "label": "收載: 32項",
          "level": 3,
          "color": "#16a34a"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "ops-vp-effective",
        "data": {
          "label": "生效: 111年7月",
          "level": 3,
          "color": "#16a34a"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "ops-vp-2022-estimated",
        "data": {
          "label": "111年推估: 192萬點",
          "level": 3,
          "color": "#16a34a"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "ops-vp-within-budget",
        "data": {
          "label": "結果: 未超預算",
          "level": 3,
          "color": "#16a34a"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "monitor",
        "data": {
          "label": "監控與趨勢",
          "level": 1,
          "direction": "right",
          "color": "#ea580c",
          "icon": "⚠️"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "monitor-current-mech",
        "data": {
          "label": "現行監控機制",
          "level": 2,
          "color": "#ea580c"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "monitor-regular-report",
        "data": {
          "label": "定期會議報告",
          "level": 3,
          "color": "#ea580c"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "monitor-5yr-reporting",
        "data": {
          "label": "五年申報期程",
          "level": 3,
          "color": "#ea580c"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "monitor-device-usage-trend",
        "data": {
          "label": "特材用量趨勢",
          "level": 2,
          "color": "#ea580c"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "monitor-yr1-high-claim",
        "data": {
          "label": "第一年: 申報量高",
          "level": 3,
          "color": "#ea580c"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "monitor-yr2-adjustment",
        "data": {
          "label": "第二年: 調整管理",
          "level": 3,
          "color": "#ea580c"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "monitor-yr3-stabilized",
        "data": {
          "label": "第三年: 趨於平穩",
          "level": 3,
          "color": "#ea580c"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "action",
        "data": {
          "label": "建議與行動",
          "level": 1,
          "direction": "left",
          "color": "#9333ea",
          "icon": "✅"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "action-continue-monitoring",
        "data": {
          "label": "持續監控費用",
          "level": 2,
          "color": "#9333ea"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "action-adjust-reporting-cycle",
        "data": {
          "label": "調整報告週期",
          "level": 2,
          "color": "#9333ea"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "action-suggest-3yr",
        "data": {
          "label": "建議: 縮短為三年",
          "level": 3,
          "color": "#9333ea"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "action-basis-drug-rules",
        "data": {
          "label": "依據: 藥物給付條例",
          "level": 3,
          "color": "#9333ea"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "action-implement-next-meeting",
        "data": {
          "label": "實施: 下次會議起",
          "level": 3,
          "color": "#9333ea"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      },
      {
        "id": "action-meeting-followup",
        "data": {
          "label": "會議討論追蹤",
          "level": 2,
          "color": "#9333ea"
        },
        "position": {
          "x": 0,
          "y": 0
        }
      }
    ],
    "edges": [
      {
        "id": "edge-root-strategy",
        "source": "root",
        "target": "strategy"
      },
      {
        "id": "edge-strategy-budget-mgmt",
        "source": "strategy",
        "target": "strategy-budget-mgmt"
      },
      {
        "id": "edge-strategy-cost-compliance",
        "source": "strategy",
        "target": "strategy-cost-compliance"
      },
      {
        "id": "edge-strategy-nhi-benefits",
        "source": "strategy",
        "target": "strategy-nhi-benefits"
      },
      {
        "id": "edge-root-ops",
        "source": "root",
        "target": "ops"
      },
      {
        "id": "edge-ops-2022-budget",
        "source": "ops",
        "target": "ops-2022-budget"
      },
      {
        "id": "edge-ops-2022-total-budget",
        "source": "ops-2022-budget",
        "target": "ops-2022-total-budget"
      },
      {
        "id": "edge-ops-2022-announced-items",
        "source": "ops-2022-budget",
        "target": "ops-2022-announced-items"
      },
      {
        "id": "edge-ops-2022-estimated-spend",
        "source": "ops-2022-budget",
        "target": "ops-2022-estimated-spend"
      },
      {
        "id": "edge-ops-2018-2022-claim",
        "source": "ops",
        "target": "ops-2018-2022-claim"
      },
      {
        "id": "edge-ops-5yr-budget",
        "source": "ops-2018-2022-claim",
        "target": "ops-5yr-budget"
      },
      {
        "id": "edge-ops-2022-estimated-claim",
        "source": "ops-2018-2022-claim",
        "target": "ops-2022-estimated-claim"
      },
      {
        "id": "edge-ops-overall-within-budget",
        "source": "ops-2018-2022-claim",
        "target": "ops-overall-within-budget"
      },
      {
        "id": "edge-ops-vertebroplasty-case",
        "source": "ops",
        "target": "ops-vertebroplasty-case"
      },
      {
        "id": "edge-ops-vp-items",
        "source": "ops-vertebroplasty-case",
        "target": "ops-vp-items"
      },
      {
        "id": "edge-ops-vp-effective",
        "source": "ops-vertebroplasty-case",
        "target": "ops-vp-effective"
      },
      {
        "id": "edge-ops-vp-2022-estimated",
        "source": "ops-vertebroplasty-case",
        "target": "ops-vp-2022-estimated"
      },
      {
        "id": "edge-ops-vp-within-budget",
        "source": "ops-vertebroplasty-case",
        "target": "ops-vp-within-budget"
      },
      {
        "id": "edge-root-monitor",
        "source": "root",
        "target": "monitor"
      },
      {
        "id": "edge-monitor-current-mech",
        "source": "monitor",
        "target": "monitor-current-mech"
      },
      {
        "id": "edge-monitor-regular-report",
        "source": "monitor-current-mech",
        "target": "monitor-regular-report"
      },
      {
        "id": "edge-monitor-5yr-reporting",
        "source": "monitor-current-mech",
        "target": "monitor-5yr-reporting"
      },
      {
        "id": "edge-monitor-device-usage-trend",
        "source": "monitor",
        "target": "monitor-device-usage-trend"
      },
      {
        "id": "edge-monitor-yr1-high-claim",
        "source": "monitor-device-usage-trend",
        "target": "monitor-yr1-high-claim"
      },
      {
        "id": "edge-monitor-yr2-adjustment",
        "source": "monitor-device-usage-trend",
        "target": "monitor-yr2-adjustment"
      },
      {
        "id": "edge-monitor-yr3-stabilized",
        "source": "monitor-device-usage-trend",
        "target": "monitor-yr3-stabilized"
      },
      {
        "id": "edge-root-action",
        "source": "root",
        "target": "action"
      },
      {
        "id": "edge-action-continue-monitoring",
        "source": "action",
        "target": "action-continue-monitoring"
      },
      {
        "id": "edge-action-adjust-reporting-cycle",
        "source": "action",
        "target": "action-adjust-reporting-cycle"
      },
      {
        "id": "edge-action-suggest-3yr",
        "source": "action-adjust-reporting-cycle",
        "target": "action-suggest-3yr"
      },
      {
        "id": "edge-action-basis-drug-rules",
        "source": "action-adjust-reporting-cycle",
        "target": "action-basis-drug-rules"
      },
      {
        "id": "edge-action-implement-next-meeting",
        "source": "action-adjust-reporting-cycle",
        "target": "action-implement-next-meeting"
      },
      {
        "id": "edge-action-meeting-followup",
        "source": "action",
        "target": "action-meeting-followup"
      }
    ]
  }
}